NCT05334329View on ClinicalTrials.gov

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 20, 2022

Primary Completion Date

June 14, 2026

Study Completion Date

June 14, 2026

Conditions
Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaRefractory Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8
Interventions
BIOLOGICAL

Antineoplastic Immune Cell

Given COH06 IV

BIOLOGICAL

Atezolizumab

Given IV

PROCEDURE

Biospecimen Collection

Correlative studies

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine

Given IV

Trial Locations (1)

92868

Chao Family Comprehensive Cancer Center University of California, Irvine, Orange

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of California, Irvine

OTHER